Detailed Information on Publication Record

SALMANTON-GARCIA, Jon, Fiona A STEWART, Sarah HERINGER, Markela KONIORDOU, Elena ALVAREZ-BARCO, Christos D ARGYROPOULOS, Sophia C THEMISTOCLEOUS, Paula VALLE-SIMON, Orly SPIVAK, Lenka SOUČKOVÁ, Christina MERAKOU, Maria Amelia MENDONCA, Ruth Joanna DAVIS, Anna Maria AZZINI, Helena H ASKLING, Sirkka VENE, Van Damme PIERRE, Angela STEINBACH, George SHIAMAKKIDES, Danila SEIDEL, Ole F OLESEN, Evgenia NOULA, Alan MACKEN, Catarina LUIS, Janina LECKLER, Odile LAUNAY, Catherine ISITT, Margot HELLEMANS, Jesus FRIAS-INIESTA, Di Marzo ROMINA, Antonio J CARCAS, George BOUSTRAS, Alberto M BOROBIA, Imre BARTA, Kerstin ALBUS, Murat AKOVA, Jordi OCHANDO, Miriam COHEN-KANDLI, Rebecca Jane COX, Petr HUSA, Ligita JANCORIENE, Patrick MALLON, Laura MARQUES, Sibylle C MELLINGHOFF, Pontus NAUCLER, Evelina TACCONELLI, Krisztina TOTH, Theoklis E ZAOUTIS, Markus ZEITLINGER, Oliver A CORNELY and Zoi-Dorothea PANA. VACCELERATE Volunteer Registry: A European study participant database to facilitate clinical trial enrolment. Vaccine. OXFORD: ELSEVIER SCI LTD, 2022, vol. 40, No 31, p. 4090-4097. ISSN 0264-410X. Available from: https://dx.doi.org/10.1016/j.vaccine.2022.05.022.

Other formats: BibTeX LaTeX RIS

TY  - JOUR
ID  - 2235702
AU  - Salmanton-Garcia, Jon - Stewart, Fiona A - Heringer, Sarah - Koniordou, Markela - Alvarez-Barco, Elena - Argyropoulos, Christos D - Themistocleous, Sophia C - Valle-Simon, Paula - Spivak, Orly - Součková, Lenka - Merakou, Christina - Mendonca, Maria Amelia - Davis, Ruth Joanna - Azzini, Anna Maria - Askling, Helena H - Vene, Sirkka - Pierre, Van Damme - Steinbach, Angela - Shiamakkides, George - Seidel, Danila - Olesen, Ole F - Noula, Evgenia - Macken, Alan - Luis, Catarina - Leckler, Janina - Launay, Odile - Isitt, Catherine - Hellemans, Margot - Frias-Iniesta, Jesus - Romina, Di Marzo - Carcas, Antonio J - Boustras, George - Borobia, Alberto M - Barta, Imre - Albus, Kerstin - Akova, Murat - Ochando, Jordi - Cohen-Kandli, Miriam - Cox, Rebecca Jane - Husa, Petr - Jancoriene, Ligita - Mallon, Patrick - Marques, Laura - Mellinghoff, Sibylle C - Naucler, Pontus - Tacconelli, Evelina - Toth, Krisztina - Zaoutis, Theoklis E - Zeitlinger, Markus - Cornely, Oliver A - Pana, Zoi-Dorothea
PY  - 2022
TI  - VACCELERATE Volunteer Registry: A European study participant database to facilitate clinical trial enrolment
JF  - Vaccine
VL  - 40
IS  - 31
SP  - 4090-4097
EP  - 4090-4097
PB  - ELSEVIER SCI LTD
SN  - 0264410X
KW  - SARS-CoV-2
KW  - Registry
KW  - Pandemic preparedness
KW  - Clinical trial
KW  - Volunteer
KW  - Vaccination campaign
KW  - COVID-19
KW  - Vaccination network
UR  - https://www.sciencedirect.com/science/article/pii/S0264410X22006053?via%3Dihub
N2  - Introduction: The coronavirus disease 2019 (COVID-19) pandemic has evidenced the key role of vaccine design, obtention, production and administration to successfully fight against infectious diseases and to provide efficient remedies for the citizens. Although clinical trials were rapidly established during this pandemic, identifying suitable study subjects can be challenging. For this reason, the University Hospital Cologne established a volunteer registry for participation in clinical trials first in Germany, which has now been incorporated into the European VACCELERATE clinical trials network and grew to a European Volunteer Registry. As such, VACCELERATE's Volunteer Registry aims to become a common entry point for potential volunteers in future clinical trials in Europe. Methods: Interested volunteers who would like to register for clinical trials in the VACCELERATE Volunteer Registry can access the registration questionnaire via http://www.vaccelerate.eu/volunteer-registry. Potential volunteers are requested to provide their current country and area of residence, contact information, including first and last name and e-mail address, age, gender, comorbidities, previous SARS-CoV-2 infection and vaccination status, and maximum distance willing to travel to a clinical trial site. The registry is open to both adults and children, complying with national legal consent requirements. Results: As of May 2022, the questionnaire is available in 12 countries and 14 languages. Up to date, more than 36,000 volunteers have registered, mainly from Germany. Within the first year since its establishment, the VACCELERATE Volunteer Registry has matched more than 15,000 volunteers to clinical trials. The VACCELERATE Volunteer Registry will be launched in further European countries in the coming months. Conclusions: The VACCELERATE Volunteer Registry is an active single-entry point for European residents interested in COVID-19 clinical trials participation in 12 countries (i.e., Austria, Cyprus, Germany, Greece, Ireland, Lithuania, Norway, Portugal, Spain, Sweden and Turkey). To date, more than 15,000 registered individuals have been connected to clinical trials in Germany alone. The registry is currently in the implementation phase in 5 additional countries (i.e., Belgium, Czech Republic, Hungary, Israel and the Netherlands).
ER  -

Basic information
Original name	VACCELERATE Volunteer Registry: A European study participant database to facilitate clinical trial enrolment
Authors	SALMANTON-GARCIA, Jon (guarantor), Fiona A STEWART, Sarah HERINGER, Markela KONIORDOU, Elena ALVAREZ-BARCO, Christos D ARGYROPOULOS, Sophia C THEMISTOCLEOUS, Paula VALLE-SIMON, Orly SPIVAK, Lenka SOUČKOVÁ (203 Czech Republic, belonging to the institution), Christina MERAKOU, Maria Amelia MENDONCA, Ruth Joanna DAVIS, Anna Maria AZZINI, Helena H ASKLING, Sirkka VENE, Van Damme PIERRE, Angela STEINBACH, George SHIAMAKKIDES, Danila SEIDEL, Ole F OLESEN, Evgenia NOULA, Alan MACKEN, Catarina LUIS, Janina LECKLER, Odile LAUNAY, Catherine ISITT, Margot HELLEMANS, Jesus FRIAS-INIESTA, Di Marzo ROMINA, Antonio J CARCAS, George BOUSTRAS, Alberto M BOROBIA, Imre BARTA, Kerstin ALBUS, Murat AKOVA, Jordi OCHANDO, Miriam COHEN-KANDLI, Rebecca Jane COX, Petr HUSA (203 Czech Republic, belonging to the institution), Ligita JANCORIENE, Patrick MALLON, Laura MARQUES, Sibylle C MELLINGHOFF, Pontus NAUCLER, Evelina TACCONELLI, Krisztina TOTH, Theoklis E ZAOUTIS, Markus ZEITLINGER, Oliver A CORNELY and Zoi-Dorothea PANA.
Edition	Vaccine, OXFORD, ELSEVIER SCI LTD, 2022, 0264-410X.

Other information
Original language	English
Type of outcome	Article in a journal
Field of Study	30104 Pharmacology and pharmacy
Country of publisher	United Kingdom of Great Britain and Northern Ireland
Confidentiality degree	is not subject to a state or trade secret
WWW	URL
Impact factor	Impact factor: 5.500
RIV identification code	RIV/00216224:14110/22:00127302
Organization unit	Faculty of Medicine
Doi	http://dx.doi.org/10.1016/j.vaccine.2022.05.022
UT WoS	000832911500003
Keywords in English	SARS-CoV-2; Registry; Pandemic preparedness; Clinical trial; Volunteer; Vaccination campaign; COVID-19; Vaccination network
Tags	14110214, 14110516, rivok
Tags	International impact, Reviewed
Changed by	Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 30/11/2022 14:12.

Abstract
Introduction: The coronavirus disease 2019 (COVID-19) pandemic has evidenced the key role of vaccine design, obtention, production and administration to successfully fight against infectious diseases and to provide efficient remedies for the citizens. Although clinical trials were rapidly established during this pandemic, identifying suitable study subjects can be challenging. For this reason, the University Hospital Cologne established a volunteer registry for participation in clinical trials first in Germany, which has now been incorporated into the European VACCELERATE clinical trials network and grew to a European Volunteer Registry. As such, VACCELERATE's Volunteer Registry aims to become a common entry point for potential volunteers in future clinical trials in Europe. Methods: Interested volunteers who would like to register for clinical trials in the VACCELERATE Volunteer Registry can access the registration questionnaire via http://www.vaccelerate.eu/volunteer-registry. Potential volunteers are requested to provide their current country and area of residence, contact information, including first and last name and e-mail address, age, gender, comorbidities, previous SARS-CoV-2 infection and vaccination status, and maximum distance willing to travel to a clinical trial site. The registry is open to both adults and children, complying with national legal consent requirements. Results: As of May 2022, the questionnaire is available in 12 countries and 14 languages. Up to date, more than 36,000 volunteers have registered, mainly from Germany. Within the first year since its establishment, the VACCELERATE Volunteer Registry has matched more than 15,000 volunteers to clinical trials. The VACCELERATE Volunteer Registry will be launched in further European countries in the coming months. Conclusions: The VACCELERATE Volunteer Registry is an active single-entry point for European residents interested in COVID-19 clinical trials participation in 12 countries (i.e., Austria, Cyprus, Germany, Greece, Ireland, Lithuania, Norway, Portugal, Spain, Sweden and Turkey). To date, more than 15,000 registered individuals have been connected to clinical trials in Germany alone. The registry is currently in the implementation phase in 5 additional countries (i.e., Belgium, Czech Republic, Hungary, Israel and the Netherlands).

Abstract

Introduction: The coronavirus disease 2019 (COVID-19) pandemic has evidenced the key role of vaccine design, obtention, production and administration to successfully fight against infectious diseases and to provide efficient remedies for the citizens. Although clinical trials were rapidly established during this pandemic, identifying suitable study subjects can be challenging. For this reason, the University Hospital Cologne established a volunteer registry for participation in clinical trials first in Germany, which has now been incorporated into the European VACCELERATE clinical trials network and grew to a European Volunteer Registry. As such, VACCELERATE's Volunteer Registry aims to become a common entry point for potential volunteers in future clinical trials in Europe. Methods: Interested volunteers who would like to register for clinical trials in the VACCELERATE Volunteer Registry can access the registration questionnaire via http://www.vaccelerate.eu/volunteer-registry. Potential volunteers are requested to provide their current country and area of residence, contact information, including first and last name and e-mail address, age, gender, comorbidities, previous SARS-CoV-2 infection and vaccination status, and maximum distance willing to travel to a clinical trial site. The registry is open to both adults and children, complying with national legal consent requirements. Results: As of May 2022, the questionnaire is available in 12 countries and 14 languages. Up to date, more than 36,000 volunteers have registered, mainly from Germany. Within the first year since its establishment, the VACCELERATE Volunteer Registry has matched more than 15,000 volunteers to clinical trials. The VACCELERATE Volunteer Registry will be launched in further European countries in the coming months. Conclusions: The VACCELERATE Volunteer Registry is an active single-entry point for European residents interested in COVID-19 clinical trials participation in 12 countries (i.e., Austria, Cyprus, Germany, Greece, Ireland, Lithuania, Norway, Portugal, Spain, Sweden and Turkey). To date, more than 15,000 registered individuals have been connected to clinical trials in Germany alone. The registry is currently in the implementation phase in 5 additional countries (i.e., Belgium, Czech Republic, Hungary, Israel and the Netherlands).

Links
101037867, interní kód MU	Name: VACCELERATE - European Corona Vaccine Trial Accelerator Platform (Acronym: VACCELERATE)
101037867, interní kód MU	Investor: European Union, VACCELERATE - European Corona Vaccine Trial Accelerator Platform, Health, demographic change and wellbeing (Societal Challenges)